ArticleOncology reports2025
Overexpression of ATP1B2 promotes cancer cell migration and inhibits apoptosis in patients with esophageal squamous cell carcinoma.
Article in Oncology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Identification the Tumor Mechanics-Related Biomarkers in Gastric Cancer Patients Based on Bioinformatics and Machine Learning.International journal of general medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The present study aimed to investigate the expression of ATP1B2 in esophageal squamous cell carcinoma (ESCC) and its biological effects. A total of 44 patients with ESCC who underwent surgical resection at Taihe Hospital between December 1, 2017 and December 1, 2018 were enrolled. The expression levels of ATP1B2 in cancerous and adjacent normal tissues were assessed. The present study also examined the associations between ATP1B2 expression and clinicopathological features and patient prognosis. The influence of ATP1B2 on ESCC cell proliferation, migration, cell cycle progression and apoptosis was evaluated using the methylcyclopentadienyl manganese tricarbonyl assay, plate cloning, scratch assay and flow cytometry. Furthermore, the effects of ouabain on these cellular processes were investigated. The results demonstrated that patients with high ATP1B2 expression exhibited significantly shorter overall survival than did those with low ATP1B2 expression (37.3 months vs. 43.1 months; Z=7.52; P<0.05). ATP1B2 expression, tumor invasion and lymph node metastasis were significantly associated (P<0.05). Notably, the overexpression of ATP1B2 correlated with reduced survival rates. ATP1B2 knockdown hindered cell migration and induced apoptosis, whereas ATP1B2 overexpression facilitated migration and impeded apoptosis. Ouabain treatment suppressed proliferation and migration in cells overexpressing ATP1B2 and caused cell cycle arrest in the G
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.